10 XP   0   0   5

Verrica Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Verrica together

I guess you are interested in Verrica Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Verrica Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Verrica Pharmaceuticals Inc

I send you an email if I find something interesting about Verrica Pharmaceuticals Inc.

Quick analysis of Verrica (30 sec.)










What can you expect buying and holding a share of Verrica? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.03
Expected worth in 1 year
$-1.44
How sure are you?
23.3%

+ What do you gain per year?

Total Gains per Share
$-1.47
Return On Investment
-19.7%

For what price can you sell your share?

Current Price per Share
$7.50
Expected price per share
$6.54 - $9.36
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Verrica (5 min.)




Live pricePrice per Share (EOD)

$7.50

Intrinsic Value Per Share

$-13.18 - $-15.56

Total Value Per Share

$-13.15 - $-15.53

2. Growth of Verrica (5 min.)




Is Verrica growing?

Current yearPrevious yearGrowGrow %
How rich?$1.5m$41.4m-$11.7m-39.5%

How much money is Verrica making?

Current yearPrevious yearGrowGrow %
Making money-$20.1m-$6m-$14.1m-70.0%
Net Profit Margin-2,164.6%-7,505.8%--

How much money comes from the company's main activities?

3. Financial Health of Verrica (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#777 / 966

Most Revenue
#439 / 966

Most Profit
#701 / 966

Most Efficient
#795 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Verrica? (5 min.)

Welcome investor! Verrica's management wants to use your money to grow the business. In return you get a share of Verrica.

What can you expect buying and holding a share of Verrica?

First you should know what it really means to hold a share of Verrica. And how you can make/lose money.

Speculation

The Price per Share of Verrica is $7.5. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Verrica.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Verrica, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.03. Based on the TTM, the Book Value Change Per Share is $-0.37 per quarter. Based on the YOY, the Book Value Change Per Share is $0.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Verrica.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.44-5.8%-0.44-5.8%-0.13-1.8%-0.24-3.2%-0.19-2.5%
Usd Book Value Change Per Share-0.39-5.3%-0.37-4.9%0.233.0%-0.10-1.3%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.39-5.3%-0.37-4.9%0.233.0%-0.10-1.3%0.000.0%
Usd Price Per Share5.92-5.72-3.52-8.83-7.72-
Price to Earnings Ratio-3.38--3.66-93.81-2.06--1.63-
Price-to-Total Gains Ratio-15.02--15.64--9.89--40.17--43.44-
Price to Book Ratio182.00-52.04-3.78-17.39-12.42-
Price-to-Total Gains Ratio-15.02--15.64--9.89--40.17--43.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.5
Number of shares133
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.37-0.10
Usd Total Gains Per Share-0.37-0.10
Gains per Quarter (133 shares)-49.03-12.76
Gains per Year (133 shares)-196.14-51.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-196-2060-51-61
20-392-4020-102-112
30-588-5980-153-163
40-785-7940-204-214
50-981-9900-255-265
60-1177-11860-306-316
70-1373-13820-357-367
80-1569-15780-408-418
90-1765-17740-459-469
100-1961-19700-510-520

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%2.028.00.06.7%2.028.00.06.7%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%7.020.03.023.3%7.020.03.023.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.030.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%7.020.03.023.3%7.020.03.023.3%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Verrica

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Fundamental data was last updated by Penke on 2024-06-15 23:26:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Verrica Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Verrica earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Verrica to the Biotechnology industry mean.
  • A Net Profit Margin of -531.4% means that $-5.31 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Verrica Pharmaceuticals Inc:

  • The MRQ is -531.4%. The company is making a huge loss. -2
  • The TTM is -2,164.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-531.4%TTM-2,164.6%+1,633.2%
TTM-2,164.6%YOY-7,505.8%+5,341.2%
TTM-2,164.6%5Y-2,041.0%-123.5%
5Y-2,041.0%10Y-1,360.7%-680.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-531.4%-168.0%-363.4%
TTM-2,164.6%-209.9%-1,954.7%
YOY-7,505.8%-242.3%-7,263.5%
5Y-2,041.0%-401.7%-1,639.3%
10Y-1,360.7%-532.2%-828.5%
1.1.2. Return on Assets

Shows how efficient Verrica is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Verrica to the Biotechnology industry mean.
  • -30.7% Return on Assets means that Verrica generated $-0.31 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Verrica Pharmaceuticals Inc:

  • The MRQ is -30.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -26.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.7%TTM-26.0%-4.7%
TTM-26.0%YOY-10.4%-15.6%
TTM-26.0%5Y-13.9%-12.1%
5Y-13.9%10Y-41.2%+27.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.7%-11.9%-18.8%
TTM-26.0%-11.9%-14.1%
YOY-10.4%-11.3%+0.9%
5Y-13.9%-13.5%-0.4%
10Y-41.2%-14.9%-26.3%
1.1.3. Return on Equity

Shows how efficient Verrica is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Verrica to the Biotechnology industry mean.
  • -1,344.6% Return on Equity means Verrica generated $-13.45 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Verrica Pharmaceuticals Inc:

  • The MRQ is -1,344.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -386.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1,344.6%TTM-386.9%-957.7%
TTM-386.9%YOY-23.8%-363.2%
TTM-386.9%5Y-94.9%-292.1%
5Y-94.9%10Y-181.5%+86.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,344.6%-14.2%-1,330.4%
TTM-386.9%-15.7%-371.2%
YOY-23.8%-14.3%-9.5%
5Y-94.9%-19.2%-75.7%
10Y-181.5%-19.7%-161.8%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Verrica Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Verrica is operating .

  • Measures how much profit Verrica makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Verrica to the Biotechnology industry mean.
  • An Operating Margin of -486.1% means the company generated $-4.86  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Verrica Pharmaceuticals Inc:

  • The MRQ is -486.1%. The company is operating very inefficient. -2
  • The TTM is -2,098.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-486.1%TTM-2,098.2%+1,612.1%
TTM-2,098.2%YOY-8,135.2%+6,037.0%
TTM-2,098.2%5Y-2,128.9%+30.7%
5Y-2,128.9%10Y-1,419.3%-709.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-486.1%-354.6%-131.5%
TTM-2,098.2%-225.9%-1,872.3%
YOY-8,135.2%-252.2%-7,883.0%
5Y-2,128.9%-428.3%-1,700.6%
10Y-1,419.3%-531.1%-888.2%
1.2.2. Operating Ratio

Measures how efficient Verrica is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 5.86 means that the operating costs are $5.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Verrica Pharmaceuticals Inc:

  • The MRQ is 5.861. The company is inefficient in keeping operating costs low. -1
  • The TTM is 22.812. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ5.861TTM22.812-16.950
TTM22.812YOY82.549-59.737
TTM22.8125Y21.996+0.815
5Y21.99610Y14.664+7.332
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.8613.004+2.857
TTM22.8123.332+19.480
YOY82.5493.502+79.047
5Y21.9965.271+16.725
10Y14.6646.915+7.749
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Verrica Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Verrica is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.17 means the company has $3.17 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Verrica Pharmaceuticals Inc:

  • The MRQ is 3.169. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.424. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.169TTM6.424-3.254
TTM6.424YOY12.634-6.210
TTM6.4245Y8.687-2.263
5Y8.68710Y11.498-2.812
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1693.767-0.598
TTM6.4244.000+2.424
YOY12.6344.905+7.729
5Y8.6875.883+2.804
10Y11.4986.286+5.212
1.3.2. Quick Ratio

Measures if Verrica is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Verrica to the Biotechnology industry mean.
  • A Quick Ratio of 2.92 means the company can pay off $2.92 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Verrica Pharmaceuticals Inc:

  • The MRQ is 2.919. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.171. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.919TTM6.171-3.252
TTM6.171YOY12.123-5.951
TTM6.1715Y11.462-5.290
5Y11.46210Y15.709-4.247
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9193.054-0.135
TTM6.1713.506+2.665
YOY12.1234.756+7.367
5Y11.4625.757+5.705
10Y15.7096.338+9.371
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Verrica Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Verrica assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Verrica to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.98 means that Verrica assets are financed with 97.7% credit (debt) and the remaining percentage (100% - 97.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Verrica Pharmaceuticals Inc:

  • The MRQ is 0.977. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.602. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.977TTM0.602+0.375
TTM0.602YOY0.248+0.354
TTM0.6025Y0.408+0.195
5Y0.40810Y0.383+0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9770.330+0.647
TTM0.6020.342+0.260
YOY0.2480.287-0.039
5Y0.4080.368+0.040
10Y0.3830.382+0.001
1.4.2. Debt to Equity Ratio

Measures if Verrica is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Verrica to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4,285.6% means that company has $42.86 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Verrica Pharmaceuticals Inc:

  • The MRQ is 42.856. The company is unable to pay all its debts with equity. -1
  • The TTM is 11.851. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ42.856TTM11.851+31.005
TTM11.851YOY0.789+11.062
TTM11.8515Y3.029+8.822
5Y3.02910Y2.363+0.666
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ42.8560.365+42.491
TTM11.8510.415+11.436
YOY0.7890.370+0.419
5Y3.0290.443+2.586
10Y2.3630.476+1.887
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Verrica Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Verrica generates.

  • Above 15 is considered overpriced but always compare Verrica to the Biotechnology industry mean.
  • A PE ratio of -3.38 means the investor is paying $-3.38 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Verrica Pharmaceuticals Inc:

  • The EOD is -4.287. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.384. Based on the earnings, the company is expensive. -2
  • The TTM is -3.665. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.287MRQ-3.384-0.903
MRQ-3.384TTM-3.665+0.281
TTM-3.665YOY93.807-97.472
TTM-3.6655Y2.063-5.727
5Y2.06310Y-1.633+3.696
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.287-2.341-1.946
MRQ-3.384-2.997-0.387
TTM-3.665-2.882-0.783
YOY93.807-3.553+97.360
5Y2.063-6.262+8.325
10Y-1.633-6.288+4.655
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Verrica Pharmaceuticals Inc:

  • The EOD is -4.369. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.449. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.533. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.369MRQ-3.449-0.920
MRQ-3.449TTM-6.533+3.084
TTM-6.533YOY-1.283-5.250
TTM-6.5335Y-7.279+0.746
5Y-7.27910Y-8.750+1.471
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.369-2.932-1.437
MRQ-3.449-3.739+0.290
TTM-6.533-3.776-2.757
YOY-1.283-4.917+3.634
5Y-7.279-7.942+0.663
10Y-8.750-8.503-0.247
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Verrica is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 182.00 means the investor is paying $182.00 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Verrica Pharmaceuticals Inc:

  • The EOD is 230.574. Based on the equity, the company is expensive. -2
  • The MRQ is 182.000. Based on the equity, the company is expensive. -2
  • The TTM is 52.042. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD230.574MRQ182.000+48.574
MRQ182.000TTM52.042+129.958
TTM52.042YOY3.782+48.260
TTM52.0425Y17.392+34.649
5Y17.39210Y12.421+4.971
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD230.5741.843+228.731
MRQ182.0002.249+179.751
TTM52.0422.301+49.741
YOY3.7822.412+1.370
5Y17.3923.782+13.610
10Y12.4214.212+8.209
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Verrica Pharmaceuticals Inc.

3.1. Institutions holding Verrica Pharmaceuticals Inc

Institutions are holding 42.311% of the shares of Verrica Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Perceptive Advisors LLC16.73540.7299709918200
2024-03-31venBio Select Advisor LLC9.42950.2762399999900
2024-03-31FMR Inc3.55790.000615092491860.0123
2024-03-31Vanguard Group Inc2.99080.0002126871076090.6034
2024-03-31BlackRock Inc2.62630.00021114060-21683-1.9091
2024-03-31Geode Capital Management, LLC1.05920.0003449309196324.569
2024-03-31State Street Corporation0.97270.0001412603233365.9949
2024-03-31Northern Trust Corp0.46850.0002198722-159-0.0799
2024-03-31Deutsche Bank AG0.43280.000518357498022114.5759
2024-03-31BML Capital Management LLC0.42430.702618000000
2024-03-31Steel Peak Wealth Management LLC0.32520.04111379366000.4369
2024-03-31Morgan Stanley - Brokerage Accounts0.31640.00011342162291120.584
2024-03-31Miracle Mile Advisors, INC.0.27870.017611822100
2024-03-31Wellington Management Company LLP0.24140.00011023851023850
2024-03-31Nuveen Asset Management, LLC0.2240.00029503200
2024-03-31Bridgeway Capital Management, LLC0.19380.009982200-24550-22.9977
2024-03-31Kornitzer Capital Management Inc0.1750.00817425100
2024-03-31Charles Schwab Investment Management Inc0.13050.00015535600
2024-03-31Bank of New York Mellon Corp0.1280.000154287-1442-2.5875
2024-03-31Kovitz Investment Group Partners, LLC0.11820.00385012500
Total 40.82861.791917319417+226847+1.3%

3.2. Funds holding Verrica Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Fidelity Select Biotechnology2.33490.1594990469-518300-34.3525
2024-04-30Vanguard Total Stock Mkt Idx Inv1.92340.000481589300
2024-05-30iShares Russell 2000 ETF1.18520.007150277338280.7672
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr0.68190.002128924900
2024-03-31Fidelity Small Cap Index0.48690.0046206539-5421-2.5576
2024-04-30DWS Small Cap Core S0.41180.158317470000
2024-04-30Small Cap Core Equity Composite0.41180.15831747001747000
2024-05-30iShares Russell 2000 Growth ETF0.410.013217391200
2024-04-30State St Russell Sm/Mid Cp® Indx NL Cl C0.3310.002414040000
2024-04-30Fidelity Extended Market Index0.2650.0021112402-1019-0.8984
2024-04-30Vanguard Russell 2000 ETF0.18420.0057781252720.3494
2024-05-31State St Russell Sm Cap® Indx SL Cl I0.17960.00697620000
2024-03-31Bridgeway Ultra-Small Company Market0.17680.230475000-24550-24.661
2024-03-31Buffalo Early Stage Growth Fd0.1750.56117425100
2024-03-31Kornitzer Early Stage Growth0.1750.57727425100
2024-03-31Nuveen Equity Index R60.15690.00096655600
2023-12-31NT R2000 Growth Index Fund - NL0.14670.01236222400
2024-03-31NT R2000 Index Fund - NL0.14080.004759726460.0771
2023-09-30BlackRock Extended Mkt Composite0.11760.0014499043650.7368
2024-03-31Northern Trust Russell 2000 Growth Index0.11310.0099479848911.892
Total 10.00761.91844245258-369188-8.7%

3.3. Insider Transactions

Insiders are holding 39.07% of the shares of Verrica Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-28Perceptive Advisors LlcBUY1261167.08
2023-12-26Perceptive Advisors LlcBUY546526.49
2023-12-21Perceptive Advisors LlcBUY2000006.17
2023-12-18Perceptive Advisors LlcBUY4569235.41
2023-12-15Perceptive Advisors LlcBUY5000005.97
2023-11-14Joe BonaccorsoSELL215802.93
2023-07-24Christopher G HayesSELL337894.83
2023-07-24Paul B ManningBUY2000005.02
2023-07-24Ted WhiteSELL506774.83
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Verrica Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.394-0.369-6%0.227-274%-0.096-76%0.001-36458%
Book Value Per Share--0.0330.646-95%0.960-97%1.033-97%1.008-97%
Current Ratio--3.1696.424-51%12.634-75%8.687-64%11.498-72%
Debt To Asset Ratio--0.9770.602+62%0.248+294%0.408+140%0.383+155%
Debt To Equity Ratio--42.85611.851+262%0.789+5329%3.029+1315%2.363+1713%
Dividend Per Share----0%-0%-0%-0%
Eps---0.437-0.4370%-0.133-70%-0.240-45%-0.191-56%
Free Cash Flow Per Share---0.429-0.294-31%-0.090-79%-0.183-57%-0.147-66%
Free Cash Flow To Equity Per Share---0.443-0.058-87%-0.524+18%-0.140-68%-0.030-93%
Gross Profit Margin--1.0741.154-7%1.000+7%1.031+4%1.020+5%
Intrinsic Value_10Y_max---15.564--------
Intrinsic Value_10Y_min---13.178--------
Intrinsic Value_1Y_max---0.838--------
Intrinsic Value_1Y_min---0.823--------
Intrinsic Value_3Y_max---3.068--------
Intrinsic Value_3Y_min---2.917--------
Intrinsic Value_5Y_max---5.960--------
Intrinsic Value_5Y_min---5.485--------
Market Cap318150750.000+14%275183320.480264530178.043+4%152037463.185+81%379575506.646-28%330735680.897-17%
Net Profit Margin---5.314-21.646+307%-75.058+1312%-20.410+284%-13.607+156%
Operating Margin---4.861-20.982+332%-81.352+1574%-21.289+338%-14.193+192%
Operating Ratio--5.86122.812-74%82.549-93%21.996-73%14.664-60%
Pb Ratio230.574+21%182.00052.042+250%3.782+4713%17.392+946%12.421+1365%
Pe Ratio-4.287-27%-3.384-3.665+8%93.807-104%2.063-264%-1.633-52%
Price Per Share7.500+21%5.9205.724+3%3.523+68%8.833-33%7.720-23%
Price To Free Cash Flow Ratio-4.369-27%-3.449-6.533+89%-1.283-63%-7.279+111%-8.750+154%
Price To Total Gains Ratio-19.025-27%-15.017-15.643+4%-9.885-34%-40.175+168%-43.437+189%
Quick Ratio--2.9196.171-53%12.123-76%11.462-75%15.709-81%
Return On Assets---0.307-0.260-15%-0.104-66%-0.139-55%-0.412+34%
Return On Equity---13.446-3.869-71%-0.238-98%-0.949-93%-1.815-87%
Total Gains Per Share---0.394-0.369-6%0.227-274%-0.096-76%0.001-36458%
Usd Book Value--1512000.00029744500.000-95%41494250.000-96%44427400.000-97%43179933.333-96%
Usd Book Value Change Per Share---0.394-0.369-6%0.227-274%-0.096-76%0.001-36458%
Usd Book Value Per Share--0.0330.646-95%0.960-97%1.033-97%1.008-97%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.437-0.4370%-0.133-70%-0.240-45%-0.191-56%
Usd Free Cash Flow---19947000.000-13627250.000-32%-3802000.000-81%-7968850.000-60%-6380366.667-68%
Usd Free Cash Flow Per Share---0.429-0.294-31%-0.090-79%-0.183-57%-0.147-66%
Usd Free Cash Flow To Equity Per Share---0.443-0.058-87%-0.524+18%-0.140-68%-0.030-93%
Usd Market Cap318150750.000+14%275183320.480264530178.043+4%152037463.185+81%379575506.646-28%330735680.897-17%
Usd Price Per Share7.500+21%5.9205.724+3%3.523+68%8.833-33%7.720-23%
Usd Profit---20331000.000-20184250.000-1%-6059250.000-70%-10650300.000-48%-8300233.333-59%
Usd Revenue--3826000.0002228250.000+72%2159500.000+77%899100.000+326%599400.000+538%
Usd Total Gains Per Share---0.394-0.369-6%0.227-274%-0.096-76%0.001-36458%
 EOD+5 -3MRQTTM+8 -26YOY+12 -225Y+8 -2610Y+9 -25

4.2. Fundamental Score

Let's check the fundamental score of Verrica Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.287
Price to Book Ratio (EOD)Between0-1230.574
Net Profit Margin (MRQ)Greater than0-5.314
Operating Margin (MRQ)Greater than0-4.861
Quick Ratio (MRQ)Greater than12.919
Current Ratio (MRQ)Greater than13.169
Debt to Asset Ratio (MRQ)Less than10.977
Debt to Equity Ratio (MRQ)Less than142.856
Return on Equity (MRQ)Greater than0.15-13.446
Return on Assets (MRQ)Greater than0.05-0.307
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Verrica Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.715
Ma 20Greater thanMa 507.916
Ma 50Greater thanMa 1007.977
Ma 100Greater thanMa 2006.849
OpenGreater thanClose7.520
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets66,311
Total Liabilities64,799
Total Stockholder Equity1,512
 As reported
Total Liabilities 64,799
Total Stockholder Equity+ 1,512
Total Assets = 66,311

Assets

Total Assets66,311
Total Current Assets61,376
Long-term Assets4,935
Total Current Assets
Cash And Cash Equivalents 48,939
Net Receivables 7,594
Inventory 2,499
Other Current Assets 2,344
Total Current Assets  (as reported)61,376
Total Current Assets  (calculated)61,376
+/-0
Long-term Assets
Property Plant Equipment 4,479
Long-term Assets Other 452
Long-term Assets  (as reported)4,935
Long-term Assets  (calculated)4,931
+/- 4

Liabilities & Shareholders' Equity

Total Current Liabilities19,365
Long-term Liabilities45,434
Total Stockholder Equity1,512
Total Current Liabilities
Short-term Debt 1,010
Accounts payable 2,527
Other Current Liabilities 15,828
Total Current Liabilities  (as reported)19,365
Total Current Liabilities  (calculated)19,365
+/-0
Long-term Liabilities
Long term Debt 42,848
Capital Lease Obligations Min Short Term Debt2,586
Long-term Liabilities  (as reported)45,434
Long-term Liabilities  (calculated)45,434
+/-0
Total Stockholder Equity
Common Stock4
Retained Earnings -250,779
Accumulated Other Comprehensive Income -4
Other Stockholders Equity 252,291
Total Stockholder Equity (as reported)1,512
Total Stockholder Equity (calculated)1,512
+/-0
Other
Capital Stock4
Cash and Short Term Investments 48,939
Common Stock Shares Outstanding 46,484
Liabilities and Stockholders Equity 66,311
Net Debt -2,495
Net Invested Capital 44,356
Net Working Capital 42,011
Property Plant and Equipment Gross 5,779
Short Long Term Debt Total 46,444



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
544
0
0
0
9,083
29,396
104,716
98,805
91,906
85,979
81,250
76,074
68,424
94,442
87,236
79,936
74,154
108,102
99,030
88,756
80,125
71,617
63,436
49,147
44,721
68,639
62,201
97,148
81,597
66,311
66,31181,59797,14862,20168,63944,72149,14763,43671,61780,12588,75699,030108,10274,15479,93687,23694,44268,42476,07481,25085,97991,90698,805104,71629,3969,083000544
   > Total Current Assets 
544
0
0
0
9,083
28,905
104,590
98,677
89,809
84,677
79,739
74,040
64,983
90,647
83,338
73,974
65,470
102,046
93,374
83,158
74,328
65,772
57,341
43,395
39,115
63,097
56,777
91,725
77,530
61,376
61,37677,53091,72556,77763,09739,11543,39557,34165,77274,32883,15893,374102,04665,47073,97483,33890,64764,98374,04079,73984,67789,80998,677104,59028,9059,083000544
       Cash And Cash Equivalents 
527
0
0
0
8,663
27,485
103,149
38,311
89,809
24,427
19,852
10,600
9,241
54,486
48,932
17,198
10,686
44,101
24,706
20,442
15,752
10,407
5,430
32,473
34,273
59,952
55,140
84,308
69,547
48,939
48,93969,54784,30855,14059,95234,27332,4735,43010,40715,75220,44224,70644,10110,68617,19848,93254,4869,24110,60019,85224,42789,80938,311103,14927,4858,663000527
       Short-term Investments 
0
0
0
0
0
0
0
58,664
79,538
58,855
58,902
60,478
52,776
33,896
30,690
54,683
54,784
43,585
65,423
59,053
54,602
11,497
8,968
6,981
0
0
0
0
0
0
0000006,9818,96811,49754,60259,05365,42343,58554,78454,68330,69033,89652,77660,47858,90258,85579,53858,6640000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
6
0
0
0
0
0
0
0
11,500
0
0
0
431
218
419
487
56
173
4,072
4,416
7,594
7,5944,4164,0721735648741921843100011,50000000006000000000
       Other Current Assets 
17
0
0
0
420
1,420
1,441
1,702
1,343
1,389
985
2,962
2,966
2,265
3,716
2,093
2,180
2,860
3,245
3,663
3,974
43,437
42,725
3,522
4,842
3,089
1,464
3,066
2,545
2,344
2,3442,5453,0661,4643,0894,8423,52242,72543,4373,9743,6633,2452,8602,1802,0933,7162,2652,9662,9629851,3891,3431,7021,4411,42042000017
   > Long-term Assets 
0
0
0
0
0
491
126
128
2,097
1,302
1,511
2,034
3,441
3,795
3,898
5,962
8,684
6,056
5,656
5,598
5,797
5,845
6,095
5,752
5,606
5,542
5,424
5,423
4,067
4,935
4,9354,0675,4235,4245,5425,6065,7526,0955,8455,7975,5985,6566,0568,6845,9623,8983,7953,4412,0341,5111,3022,09712812649100000
       Property Plant Equipment 
0
0
0
0
0
19
112
114
255
1,288
1,497
2,000
2,201
2,420
2,517
4,599
4,938
5,109
5,371
5,334
5,797
5,703
5,626
5,531
5,606
5,173
4,988
5,423
3,615
4,479
4,4793,6155,4234,9885,1735,6065,5315,6265,7035,7975,3345,3715,1094,9384,5992,5172,4202,2012,0001,4971,2882551141121900000
       Other Assets 
0
0
0
0
0
472
14
14
499
14
14
34
1,240
1,375
1,381
1,363
1,566
947
285
9,261
295
142
469
221
276
0
436
0
0
0
00043602762214691422959,2612859471,5661,3631,3811,3751,240341414499141447200000
> Total Liabilities 
419
0
0
0
616
1,648
3,125
2,451
2,477
3,218
4,405
4,421
3,409
37,834
38,773
40,754
41,168
46,292
46,874
47,904
47,520
46,199
47,103
4,382
4,688
3,793
6,801
54,845
61,834
64,799
64,79961,83454,8456,8013,7934,6884,38247,10346,19947,52047,90446,87446,29241,16840,75438,77337,8343,4094,4214,4053,2182,4772,4513,1251,648616000419
   > Total Current Liabilities 
419
0
0
0
616
1,648
3,125
2,451
2,477
3,062
4,281
4,330
3,351
3,302
38,698
39,003
39,475
44,658
45,282
46,374
46,055
44,800
45,711
3,078
3,459
2,643
5,731
11,374
17,024
19,365
19,36517,02411,3745,7312,6433,4593,07845,71144,80046,05546,37445,28244,65839,47539,00338,6983,3023,3514,3304,2813,0622,4772,4513,1251,648616000419
       Short-term Debt 
36
36
0
0
14
7
0
0
0
122
124
127
130
133
34,844
35,225
35,513
40,899
41,247
41,593
41,944
42,255
42,583
291
297
302
309
347
700
1,010
1,01070034730930229729142,58342,25541,94441,59341,24740,89935,51335,22534,844133130127124122000714003636
       Short Long Term Debt 
36
36
0
0
14
7
0
0
0
122
0
0
0
0
34,720
34,980
35,315
40,669
41,005
41,348
41,693
41,999
42,293
0
0
0
0
0
0
0
000000042,29341,99941,69341,34841,00540,66935,31534,98034,7200000122000714003636
       Accounts payable 
67
0
0
0
167
618
1,117
1,105
960
1,136
1,473
1,010
1,185
1,103
1,297
179
348
878
783
904
845
531
714
137
507
575
2,057
1,925
2,464
2,527
2,5272,4641,9252,0575755071377145318459047838783481791,2971,1031,1851,0101,4731,1369601,1051,11761816700067
       Other Current Liabilities 
352
0
0
0
449
1,030
2,008
1,346
1,517
122
2,684
3,193
2,036
2,066
2,557
3,099
3,114
2,881
3,252
3,877
3,266
2,014
2,414
2,650
2,655
1,766
3,365
282
13,860
15,828
15,82813,8602823,3651,7662,6552,6502,4142,0143,2663,8773,2522,8813,1143,0992,5572,0662,0363,1932,6841221,5171,3462,0081,030449000352
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
156
124
91
58
34,532
75
1,751
35,315
1,634
1,592
1,530
1,465
1,399
1,392
1,304
1,229
1,150
1,070
43,471
44,810
45,434
45,43444,81043,4711,0701,1501,2291,3041,3921,3991,4651,5301,5921,63435,3151,7517534,5325891124156000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
34,434
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000034,4340000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
75
75
0
5,853
0
0
6,556
0
0
0
0
0
0
0
0
0
0
00000000006,556005,853075750000000000000
       Deferred Long Term Liability 
0
0
0
0
0
472
0
0
0
0
0
0
0
0
0
0
100
100
100
100
0
0
0
0
0
0
0
0
0
0
0000000000100100100100000000000047200000
> Total Stockholder Equity
125
-2,664
0
0
8,467
27,748
101,591
96,354
89,429
82,761
76,845
71,653
65,015
56,608
48,463
39,182
32,986
61,810
52,156
40,852
32,605
25,418
16,333
44,765
40,033
64,846
55,400
42,303
19,763
1,512
1,51219,76342,30355,40064,84640,03344,76516,33325,41832,60540,85252,15661,81032,98639,18248,46356,60865,01571,65376,84582,76189,42996,354101,59127,7488,46700-2,664125
   Common Stock
1
0
0
0
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
444444433333333333333333220001
   Retained Earnings Total Equity0000-170,042-163,453-157,521-157,604-147,436-138,966-129,426-116,597-104,822-103,886-90,909-80,423-71,014-61,192-53,555-47,465-40,464-33,083-27,007-20,268000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-104,716
-7
-17
11
38
27
20
20
32
6
1
3
-1
-2
-29
-62
-64
-29
0
0
0
0
0
-4
-400000-29-64-62-29-2-1316322020273811-17-7-104,716000000
   Capital Surplus 
0
0
0
0
0
5,555
121,856
123,365
122,526
123,211
124,269
125,178
126,594
127,599
128,851
130,528
136,868
166,626
168,751
170,277
171,597
172,913
173,998
202,311
203,482
234,884
0
0
0
0
0000234,884203,482202,311173,998172,913171,597170,277168,751166,626136,868130,528128,851127,599126,594125,178124,269123,211122,526123,365121,8565,55500000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
20,900
42,055
121,856
24,560
122,526
123,211
124,269
125,178
126,184
127,599
128,851
130,082
136,868
166,626
168,751
170,277
171,597
172,913
173,998
202,311
203,482
234,884
236,428
248,133
250,207
252,291
252,291250,207248,133236,428234,884203,482202,311173,998172,913171,597170,277168,751166,626136,868130,082128,851127,599126,184125,178124,269123,211122,52624,560121,85642,05520,9000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,124
Cost of Revenue-1,164
Gross Profit3,9603,960
 
Operating Income (+$)
Gross Profit3,960
Operating Expense-67,182
Operating Income-63,222-63,222
 
Operating Expense (+$)
Research Development20,295
Selling General Administrative33,499
Selling And Marketing Expenses0
Operating Expense67,18253,794
 
Net Interest Income (+$)
Interest Income2,234
Interest Expense-3,962
Other Finance Cost-2,305
Net Interest Income577
 
Pretax Income (+$)
Operating Income-63,222
Net Interest Income577
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-66,995-59,449
EBIT - interestExpense = -67,184
-66,995
-63,033
Interest Expense3,962
Earnings Before Interest and Taxes (EBIT)-63,222-63,033
Earnings Before Interest and Taxes (EBITDA)-62,386
 
After tax Income (+$)
Income Before Tax-66,995
Tax Provision-0
Net Income From Continuing Ops-48,313-66,995
Net Income-66,995
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses68,346
Total Other Income/Expenses Net-3,773-577
 

Technical Analysis of Verrica
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Verrica. The general trend of Verrica is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Verrica's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Verrica Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 7.733 < 8.08 < 9.36.

The bearish price targets are: 6.88 > 6.57 > 6.54.

Tweet this
Verrica Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Verrica Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Verrica Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Verrica Pharmaceuticals Inc. The current macd is -0.21519046.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Verrica price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Verrica. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Verrica price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Verrica Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartVerrica Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Verrica Pharmaceuticals Inc. The current adx is 21.59.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Verrica shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Verrica Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Verrica Pharmaceuticals Inc. The current sar is 8.37399127.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Verrica Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Verrica Pharmaceuticals Inc. The current rsi is 45.72. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Verrica Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartVerrica Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Verrica Pharmaceuticals Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Verrica price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Verrica Pharmaceuticals Inc Daily Stochastic Oscillator ChartVerrica Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Verrica Pharmaceuticals Inc. The current cci is -51.82977314.

Verrica Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartVerrica Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Verrica Pharmaceuticals Inc. The current cmo is -8.90780994.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Verrica Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartVerrica Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Verrica Pharmaceuticals Inc. The current willr is -68.28644501.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Verrica is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Verrica Pharmaceuticals Inc Daily Williams %R ChartVerrica Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Verrica Pharmaceuticals Inc. The current atr is 0.62061752.

Verrica Pharmaceuticals Inc Daily Average True Range (ATR) ChartVerrica Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Verrica Pharmaceuticals Inc. The current obv is 49,775,647.

Verrica Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartVerrica Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Verrica Pharmaceuticals Inc. The current mfi is 47.45.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Verrica Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartVerrica Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Verrica Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-05-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-05-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Verrica Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Verrica Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.715
Ma 20Greater thanMa 507.916
Ma 50Greater thanMa 1007.977
Ma 100Greater thanMa 2006.849
OpenGreater thanClose7.520
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Verrica with someone you think should read this too:
  • Are you bullish or bearish on Verrica? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Verrica? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Verrica Pharmaceuticals Inc

I send you an email if I find something interesting about Verrica Pharmaceuticals Inc.


Stay informed about Verrica Pharmaceuticals Inc.

Receive notifications about Verrica Pharmaceuticals Inc in your mailbox!